Literature DB >> 15719266

Neuro-oncology in a nutshell.

Joachim M Baehring1.   

Abstract

Mesh：

Year:  2005        PMID： 15719266     DOI： 10.1007/s11060-004-5961-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  24 in total

1.  Blood-brain barrier opened by stimulation of the parasympathetic sphenopalatine ganglion: a new method for macromolecule delivery to the brain.

Authors:  David Yarnitsky; Yossi Gross; Adi Lorian; Alon Shalev; Itschak Lamensdorf; Rinat Bornstein; Shy Shorer; Avraham Mayevsky; Kaushik P Patel; N Joan Abbott; William G Mayhan
Journal:  J Neurosurg       Date:  2004-08       Impact factor: 5.115

2.  Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas.

Authors:  Nicolas Vogt; Sandrine-Hélène Lefèvre; Françoise Apiou; Anne-Marie Dutrillaux; Andrej Cör; Pascal Leuraud; Marie-France Poupon; Bernard Dutrillaux; Michelle Debatisse; Bernard Malfoy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-21       Impact factor: 11.205

Review 3.  Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

Authors:  Roelien H Enting; Alexis Demopoulos; Lisa M DeAngelis; Lauren E Abrey
Journal:  Neurology       Date:  2004-09-14       Impact factor: 9.910

4.  Imatinib mesylate for cerebral Langerhans'-cell histiocytosis.

Authors:  Liliana Montella; Luigi Insabato; Giovannella Palmieri
Journal:  N Engl J Med       Date:  2004-09-02       Impact factor: 91.245

5.  RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

Authors:  Manuel A Friese; Jörg Wischhusen; Wolfgang Wick; Markus Weiler; Günter Eisele; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

6.  Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects.

Authors:  Karlyne M Reilly; Robert G Tuskan; Emily Christy; Dagan A Loisel; Jeremy Ledger; Roderick T Bronson; C Dahlem Smith; Shirley Tsang; David J Munroe; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-19       Impact factor: 11.205

7.  Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.

Authors:  L Bomgaars; J R Geyer; J Franklin; G Dahl; J Park; N J Winick; R Klenke; S L Berg; S M Blaney
Journal:  J Clin Oncol       Date:  2004-10-01       Impact factor: 44.544

8.  Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958-1995.

Authors:  Shuji Yonehara; Alina V Brenner; Masao Kishikawa; Peter D Inskip; Dale L Preston; Elaine Ron; Kiyohiko Mabuchi; Shoji Tokuoka
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

9.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions.

Authors:  K Hoang-Xuan; L Capelle; M Kujas; S Taillibert; H Duffau; J Lejeune; M Polivka; E Crinière; Y Marie; K Mokhtari; A F Carpentier; F Laigle; J M Simon; P Cornu; P Broët; M Sanson; J Y Delattre
Journal:  J Clin Oncol       Date:  2004-08-01       Impact factor: 44.544

10.  The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma.

Authors:  Rose Lai; Chau T Dang; Mark G Malkin; Lauren E Abrey
Journal:  Cancer       Date:  2004-08-15       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.